结核病内科治疗的现状与展望

结核病与肺部健康杂志 ›› 2012, Vol. 1 ›› Issue (1): 11-14.

结核病内科治疗的现状与展望

唐神结,肖和平

200433 同济大学附属上海市肺科医院结核病诊疗中心

收稿日期:2012-06-26 出版日期:2012-07-20 发布日期:2012-07-20
通信作者: 肖和平,Email:xiaoheping_sars@163.com

Current medical treatment of tuberculosis and its prospects

TANG Shen-jie, XIAO He-ping

Tuberculosis Center for Diagnosis and Treatment, Shanghai Pulmonary Hospital Affiliated to Tongji University, Shanghai 200433, China

Received:2012-06-26 Online:2012-07-20 Published:2012-07-20
Contact: XIAO He-ping, Email:xiaoheping_sars@163.com

摘要/Abstract

摘要： 结核病的内科治疗从最初的静养疗法、萎陷疗法,到1944年链霉素的问世及化学治疗时代,再到1965年利福平的问世及短程化疗时代,以及今天的化疗、免疫、介入等多种治疗并举的时代。面对日益加剧的耐药结核病的流行趋势,结核病内科治疗的未来无疑应着眼于抗结核新药的研制与开发、结核病治疗性疫苗的研究,以及纳米技术在结核病中的应用等。

Abstract: Medical treatment for tuberculosis has mutated from sanatoria treatment, artificial pneumothorax and artificial pneumoperitoneum therapy at the beginning to the emergence of streptomycin and chemotherapy, and then to the advent of rifampicin and short course chemotherapy, finally to current combined treatment, including chemotherapy, immunotherapy and intervention. Facing the trend of deteriorated drug resistance, medical treatment for tuberculosis in future will no doubt to be focusing on the research and development of new anti-TB drugs, the research of therapeutic vaccines as well as the application of nanotechnology in TB.

唐神结,肖和平. 结核病内科治疗的现状与展望[J]. 结核病与肺部健康杂志, 2012, 1(1): 11-14.

TANG Shen-jie, XIAO He-ping. Current medical treatment of tuberculosis and its prospects[J]. Journal of Tuberculosis and Lung Health, 2012, 1(1): 11-14.

参考文献

[1] WHO. Guidelines for the programmatic management of drug-resistant tuberculosis 2011 update. WHO/HTM/TB/2011.6. Geneva:World Health Organization, 2011.
[2] World Health Organization.Guidelines for the programmatic management of drug-resistant tuberculosis: emergency update 2008. WHO/HTM/TB/2008.402.Geneva:World Health Organization, 2008.
[3] 唐神结.耐药结核病防治手册.北京:人民卫生出版社,2009:44-150.
[4] Pinto L, Menzies D. Treatment of drug-resistant tuberculosis. Infect Drug Resist, 2011, 4:129-135.
[5] Jacobson KR,Theron D,Victor TC,et al.Treatment outcomes of isoniazid-resistant tuberculosis patients, Western Cape Province, South Africa. Clin Infect Dis, 2011,53(4):369-472.
[6] Heller T,Lessells RJ,Wallrauch CG,et al.Community-based treatment for multidrug-resistant tuberculosis in rural Kwa-Zulu-Natal, South Africa. Int J Tuberc Lung Dis,2010,14(4):420-426.
[7] 唐神结,肖和平,张青.耐多药结核病化学治疗研究的新进展.中华结核和呼吸杂志,2009,32(8):617-620.
[8] Bang D, Lillebaek T, Thomsen V, et al.Multidrug-resistant tuberculosis: treatment outcome in Denmark, 1992—2007.Scand J Infect Dis,2010,42(4):288-293.
[9] 肖和平. 耐药结核病化学治疗指南(2010年).北京:人民卫生出版社,2011:1-60.
[10] WHO.Towards universal access to diagnosis and treatment of multidrug-resistant and extensively drug-resistant tuberculosis by 2015: WHO progress report 2011. WHO/HTM/TB/2011.3. Geneva:World Health Organization, 2011.
[11] 唐神结,肖和平.广泛耐药结核病的现状与对策.中华医学杂志,2011,91(5):355-358.
[12] Anger HA, Dworkin F, Sharma S, et al. Linezolid use for treatment of multidrug-resistant and extensively drug-resistant tuberculosis, New York City, 2000—2006. J Antimicrob Chemother,2010,65(4): 775-783.
[13] Tang SJ, Zhang Q, Zeng LH, et al. Efficacy and safety of line-zolid in the treatment of extensively drug-resistant tuberculosis.Jpn J Infect Dis,2011,64(6):509-512.
[14] Dheda K, Schwander SK, Zhu B, et al. The immunology of tuberculosis: from bench to bedside. Respirology,2010,15(3):433-450.
[15] Dlugovitzky D, Stanford C, Stanford J. Immunological basis for the introduction of immunotherapy with Mycobacterium vaccae into the routine treatment of TB. Immunotherapy,2011,3(4):557-568.
[16] 唐神结,高文.临床结核病学.北京:人民卫生出版社,2011:214-244.
[17] 傅瑜.重视支气管结核的综合及介入治疗.中华结核和呼吸杂志,2011,34(5):325-326.
[18] 张杰,王娟,王婷,等.经支气管镜治疗良性瘢痕增生性气道狭窄方法的比较.中华结核和呼吸杂志,2011,34(5):334-338.
[19] Ma Z, Lienhardt C, McIlleron H, et al. Global tuberculosis drug development pipeline: the need and the reality. Lancet,2010,375(9731): 2100-2109.
[20] 唐神结,肖和平.抗结核药物研究进展.中华全科医师杂志,2011,10(11):814-816.
[21] Diacon AH, Donald PR, Pym A,et al. Randomized pilot trial of eight weeks of bedaquiline (TMC207) treatment for multidrug-resistant tuberculosis: long-term outcome, tolerability, and effect on emergence of drug resistance. Antimicrob Agents Chemother,2012,56(6):3271-3276.
[22] 黄海荣,于霞,姜广路,等.利奈唑胺治疗耐多药结核病的初步评价.中国防痨杂志,2011,33(5):275-279.
[23] Wallis RS, Jakubiec W, Mitton-Fry M,et al.Rapid evaluation in whole blood culture of regimens for XDR-TB containing PNU-100480 (sutezolid), TMC207, PA-824, SQ109, and pyrazinamide. PLoS One,2012,7(1):e30479.
[24] Reddy VM, Dubuisson T, Einck L, et al.SQ109 and PNU-100480 interact to kill Mycobacterium tuberculosis in vitro.J Antimicrob Chemother,2012,67(5):1163-1166.
[25] Tasneen R, Li SY, Peloquin CA, et al. Sterilizing activity of novel TMC207- and PA-824-containing regimens in a murine model of tuberculosis.. Antimicrob Agents Chemother, 2012, 55(12): 5485-5492.
[26] Vilaplana C, Montané E, Pinto S, et al. Double-blind, randomized, placebo-controlled Phase I Clinical Trial of the therapeutical antituberculous vaccine RUTI.Vaccine,2010,28(4):1106-1116.
[27] Aagaard C, Hoang T, Dietrich J,et al.A multistage tuberculosis vaccine that confers efficient protection before and after exposure. Nat Med, 2011,17(2): 189-194.
[28] Butov DA, Pashkov YN, Stepanenko AL, et al. Phase Ⅱb randomized trial of adjunct immunotherapy in patients with first-diagnosed tuberculosis, relapsed and multi-drug-resistant (MDR) TB. J Immune Based Ther Vaccines, 2011,9:3.
[29] Arjanova OV, Prihoda ND, Yurchenko LV, et al. Adjunct oral immunotherapy in patients with re-treated, multidrug-resistant or HIV-coinfected TB. Immunotherapy, 2011,3(2):181-191.
[30] Armstead AL, Li B. Nanomedicine as an emerging approach against intracellular pathogens. Int J Nanomedicine,2011,6:3281-3293.
[31] Jain SK, Gupta Y, Ramalingam L,et al.Lactose-conjugated PLGA nanoparticles for enhanced delivery of rifampicin to the lung for effective treatment of pulmonary tuberculosis. PDA J Pharm Sci Technol,2010,64(3):278-287.
[32] Shegokar R, Al Shaal L, Mitri K. Present status of nanoparticle research for treatment of tuberculosis. J Pharm Pharm Sci,2011,14(1):100-116.
[33] Smith JP. Nanoparticle delivery of anti-tuberculosis chemotherapy as a potential mediator against drug-resistant tuberculosis. Yale J Biol Med,2011, 84(4):361-369.
[34] Kumar G, Malhotra S, Shafiq N,et al. In vitro physicochemical characterization and short term in vivo tolerability study of ethionamide loaded PLGA nanoparticles: potentially effective agent for multidrug resistant tuberculosis. J Microencapsul,2011,28(8):717-728.